Clinical Challenges

Hand-Foot Syndrome Related to Liposomal Doxorubicin

Karen K. Swenson

Elaine M. Bell

ovarian neoplasms, doxorubicin
ONF 2010, 37(2), 137-139. DOI: 10.1188/10.ONF.137-139

Jump to a section

    References

    Al-Batran, S. E., Meerpohl, H. G., von Minckwitz, G., Atmaca, A., Kleeberg, U., Harbeck, N., … Jager, E. (2006). Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin. Oncology, 70, 141-146. doi: 10.1159/000093005
    Anderson, R., Jatoi, A., Robert, C., Wood, L. S., Keating, K. N., & Lacouture, M. E. (2009). Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist, 14, 291-302.
    Cady, F. M., Kneuper-Hall, R., & Metcalf, J. S. (2006). Histologic patterns of polyethylene glycol-liposomal doxorubicinrelated cutaneous eruptions. American Journal of Dermatopathology, 28, 168-172. doi:10.1097/01.dad.0000199880.71481.0f
    Cancer Therapy Evaluation Program. (2006). Common Terminology Criteria for Adverse Events™ [v.3.0]. Retrieved from http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
    Centocor Ortho Biotech, Inc. (2007). Doxil® (doxorubicin) [Prescribing information]. Retrieved from http://www.centocororthobiotech.com/cobi/shared/OBI/PI/DOXIL_PI.pdf
    Drake, R. D., Lin, W. M., King, M., Farrar, D., Miller, D. S., & Coleman, R. L. (2004). Oral dexamethasone attenuates Doxil®-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecologic Oncology, 94, 320-324.
    Gordinier, M. E., Dizon, D. S., Fleming, E. L., Weitzen, S., Schwartz, J., Parker, L. P., & Granai, C. O. (2006). Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia. Gynecologic Oncology, 103, 72-74. doi: 10.1016/j.ygyno.2006.01.031
    Lorusso, D., DiStefano, A., Carone, V., Fagotti, A., Pisconti, S., & Scambia, G. (2007). Pegylated liposomal doxorubicinrelated palmar-plantar erythrodysesthesia. Annals of Oncology, 18, 1159-1164. doi:10.1093/annonc/mdl477
    Markman, M., Kulp, B., & Peterson, G. (2004). Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn. Gynecologic Oncology, 94, 578-580. doi: 10.1016/j.ygyno.2004.05.002
    Rose, P. G. (2005). Pegylated liposomal doxorubicin: Optimizing the dosing schedule in ovarian cancer. Oncologist, 10, 205-214.
    Rossi, D., & Catalano, G. (2007). Pyridoxine as prophylactic therapy for PPE associated with administration of pegylated liposomal doxorubicin. Oncology, 73, 277-278.
    Tanyi, J. L., Smith, J. A., Ramos, L., Parker, C. L., Munsell, M. F., & Wolf, J. K. (2009). Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin. Gynecologic Oncology, 114, 219-224. doi: 10.1016/j.ygyno.2009.04.007
    von Moos, R., Thuerlimann, B. J. K., Aapro, M., Rayson, D., Harrold, K., Sehouli, J., … Hauschild, A. (2008). Pegylated liposomal doxorubicin-associated hand-foot syndrome. European Journal of Cancer, 44, 781-790. doi: 10.1016/j.ejca.2008.01.028
    Webster-Gandy, J. D., How, C., & Harrold, K. (2007). Palmar-plantar erythrodysesthesia (PPE). European Journal of Oncology Nursing, 11, 238-246.
    Al-Batran, S. E., Meerpohl, H. G., von Minckwitz, G., Atmaca, A., Kleeberg, U., Harbeck, N., … Jager, E. (2006). Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin. Oncology, 70, 141-146.
    Cady, F. M., Kneuper-Hall, R., & Metcalf, J. S. (2006). Histologic patterns of polyethylene glycol-liposomal doxorubicin-related cutaneous eruptions. American Journal of Dermatopathology, 28, 168-172. doi: 10.1097/01.dad.0000199880.71481.0f
    Cancer Therapy Evaluation Program. (2006). Common Terminology Criteria for Adverse Events™ [v.3.0]. Retrieved from http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
    Centocor Ortho Biotech, Inc. (2007). Doxil® (doxorubicin) [Prescribing information]. Retrieved from http://www.centocororthobiotech.com/cobi/shared/OBI/PI/DOXIL_PI.pdf
    Drake, R. D., Lin, W. M., King, M., Farrar, D., Miller, D. S., & Coleman, R. L. (2004). Oral dexamethasone attenuates Doxil®-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecologic Oncology, 94, 320-324.
    Lorusso, D., DiStefano, A., Carone, V., Fagotti, A., Pisconti, S., & Scambia, G. (2007). Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia. Annals of Oncology, 18, 1159-1164. doi: 10.1093/annonc/mdl477
    Markman, M., Kulp, B., & Peterson, G. (2004). Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn. Gynecologic Oncology, 94, 578-580.
    Rose, P. G. (2005). Pegylated liposomal doxorubicin: Optimizing the dosing schedule in ovarian cancer. Oncologist, 10, 205-214.
    Tanyi, J. L., Smith, J. A., Ramos, L., Parker, C. L., Munsell, M. F., & Wolf, J. K. (2009). Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin. Gynecologic Oncology, 114, 219-224.
    Von Moos, R., Thuerlimann, B. J. K., Aapro, M., Rayson, D., Harrold, K., Sehouli, J., … Hauschild, A. (2008). Pegylated liposomal doxorubicin-associated hand-foot syndrome. European Journal of Cancer, 44, 781-790. doi: 10.1016/j.ejca.2008.01.028